By using foundation models to analyze vast datasets, companies can create a synthetic 'standard of care' arm for single-arm Phase 1 trials. The AI matches patients based on deep clinical and genomic parameters, providing insights comparable to a much larger Phase 3 trial.

To demonstrate a long-term survival benefit without a new trial, Neuvivo hired a research firm to track down patients from the original study. By collecting "last date alive" information in a blinded fashion, they generated statistically significant survival data years after the trial concluded.

To increase the predictive power of their data, Aphaia structured its Phase 2 study to mimic a Phase 3 trial. By imposing minimal constraints on patients (e.g., no coaching or calorie restrictions), the results are more likely to reflect real-world outcomes. This reduces the risk of a performance drop-off between phases, making the asset more attractive to potential partners.

Instead of the high-risk approach of replacing a trial's control arm with digital twins, Unlearn.ai adds counterfactual data to every participant. This method increases a trial's statistical power, allowing for smaller control arms or a higher chance of success, while satisfying regulatory constraints for pivotal trials.

AAVantgarde learned from its Usher syndrome trial that capturing patient-reported outcomes is essential, especially when traditional functional endpoints like eye charts are slow to change. This strategy ensures they capture meaningful data on patient quality of life, which can be crucial for demonstrating therapeutic benefit in slowly progressing diseases.

AAVantgarde's foundational science originated from the Italian charity Teleton. This provided decades of grant-funded research and de-risked technology, showcasing a powerful, non-traditional model for biotech incubation outside of typical VC or academic spin-out routes, culminating in Teleton achieving the first-ever BLA approval for a charity.

Founder Sean Ainsworth intentionally started his pioneering AAV gene therapy in an ocular setting before any Western approvals existed. Because an intravitreal injection uses a very small vector amount, it provided a significant safety advantage and a manageable way to prove the technology before attempting systemic delivery.

AAVantgarde's focus on the eye provides a significant manufacturing (CMC) advantage. The small quantities needed for ocular delivery reduce the pressures of scale-up, a common failure point for systemic gene therapies. This allows the team to focus on quality over quantity, contributing to a perfect manufacturing record of zero failed batches.

The company intentionally makes its early research "harder in the short term" by using complex, long-term animal models. This counterintuitive strategy is designed to generate highly predictive data early, thereby reducing the massive financial risk and high failure rate of the later-stage clinical trials.